
Manoj Thakur
Articles
-
Jan 9, 2025 |
mdpi.com | Manoj Thakur |Kartik Sahoo
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
-
Dec 4, 2024 |
elifesciences.org | Sugith Badugu |Kshitiza Mohan Dhyani |Manoj Thakur |Kalappa Muniyappa
eLife Assessment This manuscript reports important data providing evidence that a 42 amino acid region of Rev7 is necessary and sufficient for interaction with the Rad50-Mre11-Xrs2 complex in budding yeast. The authors conclude that Rev7 inhibits the Rad50 ATPase and the Mre11 nuclease with the exception of ssDNA exonuclease activity.
-
Sep 26, 2024 |
biorxiv.org | Sugith Badugu |Kshitiza Mohan Dhyani |Manoj Thakur |Kalappa Muniyappa
AbstractRecent studies have shown that, in human cancer cells, the tetrameric Shieldin complex (comprising REV7, SHLD1, SHLD2, and SHLD3) facilitates non-homologous end-joining (NHEJ) while blocking homologous recombination (HR). Surprisingly, several eukaryotic species lack SHLD1, SHLD2 and SHLD3 orthologs, suggesting that Rev7 may leverage an alternative mechanism to regulate the double-strand break (DSB) repair pathway choice.
-
Feb 21, 2024 |
biorxiv.org | Sugith Badugu |Manoj Thakur |Kalappa Muniyappa |Kshitiza Mohan Dhyani
AbstractRecent studies in cancer cell lines have shown that the tetrameric Shieldin complex (comprising REV7, SHLD1, SHLD2, and SHLD3) facilitates non-homologous end-joining (NHEJ), while blocking homologous recombination (HR). Surprisingly, several eukaryotic species lack SHLD1, SHLD2 and SHLD3 orthologs, suggesting that Rev7 may leverage an alternative mechanism to regulate the double-strand break (DSB) repair pathway choice.
-
Oct 6, 2023 |
thelancet.com | Paediatric Gastroenterology |Feeding Disorders |Manoj Thakur |Nicholas Michael Croft
SummaryPrevious studies have demonstrated the tolerability and efficacy of multimatrix mesalamine in inducing and maintaining remission in adults with mild-to-moderate ulcerative colitis (UC). We evaluated the safety and efficacy of low-dose and high-dose once-daily multimatrix mesalamine in children and adolescents with mild-to-moderate UC or those in remission.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →